William Carpenter is a Psychiatry physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
One Hospital Drive, Dc067.00
Columbia, MO 65212
Telephone
573-882-8907Registry record last updated 11 Jul 2012.
Clinical trials
- Anti-Inflammatory Treatment of Schizophrenia
Sponsor: University of Maryland, Baltimore
- Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Sponsor: University of Maryland, Baltimore
- Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
Sponsor: University of Maryland, Baltimore
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Otsuka America Pharmaceutical, Inc.Program year20235 payments
- Neurocrine Biosciences, Inc.Program year20233 payments
- AbbVie Inc.Program year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
96.4%SSRI19.9%Trazodone Hcl44%Sertraline Hcl28%Escitalopram Oxalate14%Fluoxetine Hcl12%Citalopram Hbr3%Part D<11 patientsAtypical Antipsychotic16.7%Aripiprazole24%Quetiapine Fumarate21%Vraylar11%Risperidone10%Olanzapine6%Rexulti5%Quetiapine Fumarate Er5%Invega Sustenna5%Clozapine4%Caplyta2%Clozapine Odt2%Uzedy2%Paliperidone Er2%Lurasidone Hcl2%Part D<11 patients+ 15 more classes in this area
Cardiovascular
3%alpha-Adrenergic Blocker1.8%Prazosin Hcl100%Part D≥11 patientsCentral alpha-2 Adrenergic Agonist0.6%Guanfacine Hcl Er100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
0.3%Vasopressin Analog0.3%Desmopressin Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”